Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
about
Mechanisms of Comorbidities Associated With the Metabolic Syndrome: Insights from the JCR:LA-cp Corpulent Rat StrainFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewCombining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stressFenofibrate Reduces Age-related Hypercholesterolemia in Normal Rats on a Standard DietMolecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death.In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate.Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokineticsFenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study.Carbonyl reduction pathways in drug metabolism.Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease.Potential of novel drug delivery strategies for the treatment of hyperlipidemia.Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier.Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.Biopharmaceutical modeling of drug supersaturation during lipid-based formulation digestion considering an absorption sink.In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate.Role of Alternative Lipid Excipients in the Design of Self-Nanoemulsifying Formulations for Fenofibrate: Characterization, Dispersion, Digestion and Gut Permeation Studies
P2860
Q28066227-5F955677-459A-425F-BB8C-F740DCD2E48BQ28220294-C85A9E0E-6372-4EE7-BE85-76D51D2A06B6Q30054496-3EB0A01C-D9DC-4CD9-AA12-3631168B5A86Q33849118-3F6841AD-25B9-49EB-BFB6-FB02F0622B04Q34968487-CB7EA67A-80E5-41E5-ACDA-5228C7DB5E2BQ35488199-3A28BA4A-9B74-4609-9C1B-96765EAFE4DCQ36414985-94B64B6E-3D5E-4DE8-9648-9C6788EBDF75Q37021478-C04368F5-2DA8-4042-9042-F552913D4B05Q37643065-F951B388-5684-46D8-8108-2826D25578C6Q37681585-AB11D76D-4568-461F-A74E-A97D136868AFQ38156452-DAFBB47B-4EE9-4347-BC7A-97372B6FF805Q38672178-226E0D21-F88D-4A13-B778-0748EB4ACEB2Q38794030-E1A554A0-8DC7-47F3-BDA4-A855F26E51C7Q38883374-275FEE6D-0D8D-45CD-A55B-E3C13F786D02Q41809141-E0BAD4DC-9B68-4DB0-9903-38391CD5C409Q42835474-CD439F0F-1117-42E0-88AF-2128A56705C7Q43442310-64DE09B4-5CAA-4F8E-81AB-612A3F7BF0AEQ44396367-C6DC0E37-D318-4ED6-8E84-FDE1215393BEQ59129744-081A1C6F-19A8-468B-9283-8B9F2AE14781
P2860
Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Fenofibrate in the treatment o ...... oavailable tablet formulation.
@ast
Fenofibrate in the treatment o ...... oavailable tablet formulation.
@en
type
label
Fenofibrate in the treatment o ...... oavailable tablet formulation.
@ast
Fenofibrate in the treatment o ...... oavailable tablet formulation.
@en
prefLabel
Fenofibrate in the treatment o ...... oavailable tablet formulation.
@ast
Fenofibrate in the treatment o ...... oavailable tablet formulation.
@en
P1476
Fenofibrate in the treatment o ...... oavailable tablet formulation.
@en
P2093
Jadwiga Najib
P304
P356
10.1016/S0149-2918(02)80095-9
P577
2002-12-01T00:00:00Z